Clinical trials on Glioma Glioblastoma Multiforme

  • CT-EU-00111120

    Exploring New Treatments for Brain Tumors Targeting Cancer Stem Cells

    This clinical trial focuses on developing new treatments for brain tumors, specifically targeting a type of cell called cancer stem cells (CSCs) that play a crucial role in the aggressiveness and resistance to current treatments of these tumors. Brain tumors, such as Glioblastoma (GBM), are among the most aggressive and have a low survival rate, making the need for new therapeutic approaches urgent.

    The study is particularly interested in how a lipid called Sphingosine-1-phosphate (S1P) influences these cancer stem cells. S1P is involved in the tumor’s ability to grow, resist drugs, and spread, making it a potential target for new treatments. By understanding how the environment around the tumor affects these cells and their metabolism, especially under low oxygen conditions (hypoxia), researchers hope to find new ways to stop the tumor from growing and resisting treatment.

    The main goal of this project is to identify new molecular and metabolic targets that are crucial for the survival and resistance to chemotherapy of tumor stem cells. This could lead to the development of new drugs that can inhibit the proliferation of CSCs and, consequently, tumor progression.

    For patients participating in this study, researchers will be investigating specific markers related to the development and progression of brain tumors to improve diagnosis, treatment, and monitoring. This research could significantly improve the prognosis for patients suffering from brain tumors by identifying new therapeutic strategies and potential biomarkers.